Meanwhile, combination of DHODH inhibitors with other anti-cancer drugs is a promising approach to achieving clinical benefits in various tumor therapies as DHODH inhibitors alone have limited therapeutic windows and may not achieve desired outcomes. The gene discussed is DHODH; the disease is neoplasm.